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To identify genetic factors contributing to amyotrophic lateral 
sclerosis (ALS), we conducted whole-exome analyses of 
,022 index familial ALS (FALS) cases and 7,35 controls. In a 
new screening strategy, we performed gene-burden analyses 
trained with established ALS genes and identified a significant 
association between loss-of-function (LOF) NEK1 variants and 
FALS risk. Independently, autozygosity mapping for an isolated 
community in the Netherlands identified a NEK1 p.Arg26His 
variant as a candidate risk factor. Replication analyses of 
sporadic ALS (SALS) cases and independent control cohorts 
confirmed significant disease association for both p.Arg26His 
(0,589 samples analyzed) and NEK1 LOF variants (3,362 
samples analyzed). In total, we observed NEK1 risk variants 
in nearly 3% of ALS cases. NEK1 has been linked to several 
cellular functions, including cilia formation, DNA-damage 
response, microtubule stability, neuronal morphology and 
axonal polarity. Our results provide new and important insights 
into ALS etiopathogenesis and genetic etiology. 
In recent years, the combination of exome sequencing, segregation 
analysis and bioinformatic filtering has proven to be an effective strat-
egy to rapidly identify new disease genes1. Unfortunately, this method 
can be difficult to apply to disorders such as ALS, for which late age 
of onset and low-to-modest variant penetrance make it difficult to 
obtain large informative multigenerational pedigrees. Owing to high 
genetic heterogeneity, ALS is also difficult to analyze using filter-
ing methods designed to exploit unrelated patient groups2. Recently, 
we had demonstrated the utility of exome-wide rare variant burden 
(RVB) analysis as an alternate approach, identifying a replicable 
association between FALS risk and TUBA4A in a cohort of 363 cases3. 
In brief, RVB analysis is used to compare the combined frequency 
of rare variants in each gene in a case–control cohort. Candidate 
associations are identified by significant differences after multiple-
test correction. Since this initial study, we extended our data set to 
include complete exome sequencing for 1,376 index FALS cases and 
13,883 controls. Of these, 1,022 cases and 7,315 controls met all 
required data, inter-relatedness and ancestral quality control criteria 
(Supplementary Figs. 1 and 2, and Online Methods).
Successful detection of disease associations through RVB analysis 
can depend heavily on the appropriate setting of test parameters. 
As genetic loci often contain many alleles of no or low effect, prior 
filtering of variants based on minor allele frequency (MAF) and 
pathogenicity predictors can identify disease signatures otherwise 
masked by normal human variability. As appropriate MAF or patho-
genicity predictor settings may not be obvious in advance, compre-
hensive assessment of all pursuable analysis strategies is desirable but 
can in turn introduce excessive multiple-test burden. To overcome 
these limitations, we performed 308 distinct RVB analyses of ten 
well-established ALS genes using 44 functional and 7 MAF filters 
(Fig. 1a). All tests included correction for gene coverage and ancestral 
covariates (Online Methods). In the final cohort, 72 cases and 
0 controls harbored known ALS pathogenic mutations in these ten 
genes (Online Methods). An additional 26 cases harbored a repeat 
expansion in the C9orf72 gene. Tests differed in their capacity to 
detect individual known ALS genes (Supplementary Table 1), but 
we achieved the highest net sensitivity when we restricted analyses to 
variants with MAF < 0.001 and functional classifications of either non-
sense, splice-altering4 or deemed deleterious by functional analysis 
through hidden Markov models (FATHMM)5. Under these settings, 
four genes exhibited disease association at exome-wide (Bonferroni-
corrected P < 2.5 × 10−6) significance (SOD1, TARDBP, UBQLN2 and 
FUS), three achieved near exome-wide significance (TUBA4A, TBK1 
and VCP), and three displayed modest to marginal disease association 
(PFN1, VAPB and OPTN) (Fig. 1b). Genes exhibiting the strongest 
disease associations included those reported as major ALS genes in 
population-based studies, whereas those exhibiting weaker associa-
tions are believed to constitute rarer causes of disease.
Extension of the optimal known ALS gene parameters to all protein- 
coding genes identified one new gene displaying exome-wide sig-
nificant disease association (Fig. 1b). The gene, NEK1 (odds ratio 
(OR) = 8.2, P = 1.7 × 10−6), encodes the serine/threonine kinase NIMA 
(never in mitosis gene-A)-related kinase. Retesting NEK1 under 
alternate analysis parameters identified strong disease associations 
across most analysis strategies, particularly where we included LOF 
(nonsense and predicted splice-altering) variants (Supplementary 
Table 2 and Supplementary Fig. 3). We observed no evidence for 
systematic genomic inflation (λ = 0.95), confounding related to 
sample ascertainment (Supplementary Fig. 4) or case–control 
biases in NEK1 gene coverage (Supplementary Fig. 5). Removal of 
samples carrying rare variants of known ALS genes did not influence 
the association (OR = 8.9, P = 7.3 × 10−7).
In an independent line of research, we performed whole-genome 
sequencing for four ALS patients from an isolated community 
in the Netherlands (population < 25,000). We observed high 
inbreeding coefficients for each of the four patients, confirm-
ing their high degree of relatedness and supporting a restricted 
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genetic lineage (Supplementary Fig. 6). Autozygosity mapping, 
allowing for genetic heterogeneity, identified four candidate dis-
ease variants occurring in detectable runs of homozygosity (ROH) 
(Supplementary Fig. 7). These variants included a p.Arg261His 
variant of NEK1. Two of the four SALS cases were homozygous 
for p.Arg261His and two were heterozygous, raising the possibility 
that even a single copy of the allele may increase disease risk. 
Clinical evaluation of the four cases did not find any overt dif-
ferences in disease phenotype. None of the other three candidate 
variants exhibited homozygosity in multiple patients or occurred 
at all in more than two patients. Analysis of the region identi-
fied a shared p.Arg261His haplotype spanning 3 Mb in all four 
samples (Supplementary Table 3).
To validate the risk effects of p.Arg261His, we tested for disease asso-
ciation among 6,172 SALS cases and 4,417 matched controls from eight 
countries (Supplementary Figs. 8 and 9, and Online Methods). We gen-
otyped this cohort using the Illumina exome chip or by whole-genome 
sequencing, allowing for checking of any overlap or detectable relatedness 
to the FALS case–control cohort, which was not present. Meta-analysis 
of all independent population strata identified a clear minor allele excess 
in cases with a combined significance of P = 4.8 × 10−5 and OR = 2.4 
(Fig. 2). We also observed disease association in the FALS case–control 
data (OR = 2.7, P = 1.5 × 10−3) and a meta-analysis of FALS, SALS and 
all controls combined (OR = 2.4, P = 1.2 × 10−7).
DNA availability facilitated segregation analysis of only one NEK1 
LOF variant, a p.Arg550* variant, which we also detected in the 
affected mother of the identified proband. To validate the effect of 
LOF variants observed in FALS and assess any potential contribution 
to sporadic disease, we analyzed full sequencing data of the NEK1 cod-
ing region for 2,303 SALS cases and 1,059 controls (Supplementary 
Fig. 3 and Online Methods). RVB analysis confirmed a significant 
excess of LOF variants in cases (23/2,303 SALS samples versus 
0/1,059 controls, OR = 22.2, P = 1.5 × 10−4; Supplementary Table 2). 
Meta-analysis of discovery and replication LOF analyses yielded a 
combined significance of P = 3.4 × 10−8 and OR = 8.8.
In total, we detected 120 predicted nonsynonymous NEK1 variants 
in FALS samples, SALS samples and controls. These were distributed 
throughout the gene including in the sequence encoding protein 
kinase domain (PKD) and six coiled-coil domains thought to be 
involved in mediating protein–protein interactions (Supplementary 
Fig. 3). After conditioning for LOF variants and p.Arg261His, we 
observed tentative excesses of case variants in analyses of rarer 
variant categories, but larger sample sizes will be required to con-
firm the pathogenicity beyond p.Arg261His and LOF variants 
(Supplementary Table 4). Analysis of other members of the NEK 
gene family (NEK2−NEK11) identified no associations in the FALS 
data set meeting multiple-test criteria (Supplementary Table 5).
Although no other gene achieved discovery significance, ten 
candidate loci exhibited P < 1.0 × 10−3 in the FALS discovery analysis 
(Table 1). These included the gene encoding the SNARE (soluble 
NSF attachment protein receptor) complex protein synataxin 12 
(STX12, OR = 33.1, P = 9.7 × 10−5). Analysis of the SALS replication 
cohort identified missense variants in 5/2,303 cases versus 0/1,059 in 
controls. However, the cohort was not sufficiently powered to assess 
events of this frequency, and larger sample sizes will be required to 
establish effects on ALS risk (Supplementary Table 6). Another iden-
tified candidate gene was the known hereditary spastic paraplegia 
gene KIF5A6 (OR = 7.1, P = 4.8 × 10−4); however, no observed eleva-
tions in patient variant frequencies within the SALS replication cohort 
reached statistical significance (Supplementary Table 7).
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a bFigure 1 RVB analysis of FALS exomes.  
(a) RVB analyses of 1,022 index FALS cases 
and 7,315 controls for 10 known ALS genes,  
to assess 308 different combinations of  
MAF and functional prediction filters 
(supplementary table 1). The set of analysis 
parameters achieving the highest sensitivity  
for known ALS genes was identified as  
that achieving the highest area under the  
curve (AUC) in a plot of sensitivity (proportion  
of training genes achieving significance)  
across an increasing minimum P-value 
threshold. Dotted vertical line denotes 
Bonferroni-corrected P value for exome- 
wide significance. (b) Extension of the  
highest performing known gene-trained  
analysis to the entire exome. Threshold  
for exome-wide significance is denoted by the dotted red line. λ, observed genomic inflation factor. ‘Obs’ describes the P-value distribution for the 
observed data. ‘Exp’ describes the P-value distribution under null expectation.
Cohort
FALS
SALS
Belgium
Spain/Italy
Germany
Ireland
Netherlands
UK
United States
Total
FALS + SALS
Cases
1,022
466
472
1,229
565
1,839
1,335
266
6,172
7,194
Controls
7,315
476
183
288
526
1,982
893
69
4,417
11,732
MAF (cases)
0.0086
0.0097
0.0074
0.0090
0.0044
0.0109
0.0049
0.0056
0.0080
0.0081
MAF (controls)
0.0036
0.0053
0.0055
0.0017
0.0019
0.0035
0.0022
0.0072
0.0033
0.0035
  OR
2.66
1.81
1.36
5.27
2.32
2.99
2.59
0.84
2.41
2.41
95% CI
1.48−4.57
0.60−5.51
0.28−6.58
0.71−38.81
0.45−12.05
1.63−5.47
0.71−6.69
0.08−8.29
1.58−3.71
1.57−3.71
P
1.5 × 10–3
4.8 × 10–5
1.2 × 10–7
0.10 1.0 10.0
Figure 2 Replication analysis of NEK1 
p.Arg261His. NEK1 p.Arg261His genotypes 
were ascertained for 1,022 FALS samples, 
6,172 SALS samples and 11,732 controls. 
The SALS cohort was divided into seven 
geographically based case–control strata.  
Logistic regression was used to conduct tests  
of allelic association for all subcohorts and  
was followed by a fixed-effects meta-analysis.  
In the distribution of OR estimates across  
study cohorts (right), vertical dotted line 
denotes OR estimated under meta-analysis.  
CI, confidence interval.
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NEK1 has been previously described as a candidate gene for 
ALS7,8. Here our findings show that NEK1 in fact constitutes a major 
ALS-associated gene with risk variants present in ~3% of European and 
European-American ALS cases. We identified LOF variants in 1.2% 
of FALS samples (OR = 8.2) and 1.0% of SALS samples (OR = 22.2) 
versus 0.17% of controls, whereas we identified the p.Arg261His vari-
ant in 1.7% of FALS samples (OR = 2.7) and 1.6% of SALS samples 
(OR = 2.4) versus 0.69% of controls. We identified variants of unknown 
clinical importance (missense, MAF < 0.001) in a further 1.8% of 
FALS samples and 1.3% of SALS samples versus 1.2% of controls. 
In comparison, risk variants in previously established ALS genes occur 
at approximately the following percentages: C9orf72, <10%; SOD1, 
<2%; TARDBP, <1%; FUS, <1%; and others, <<1% or uncertain9–12. 
However, caution must be taken when comparing the frequency of 
variants or mutations that differ in penetrance (i.e., highly penetrant 
mutations to lower-penetrance risk variants). Furthermore, assess-
ment of the true odds ratio for variants in a gene may be difficult 
because of the presence of neutral variants that dilute out the observed 
effect. The actual odds ratio may therefore be even higher for specific 
subsets of patient variants. The LOF variants in NEK1 displayed a 
higher odds ratio relative to p.Arg261His. The p.Arg261His variant 
occurs adjacent to the protein kinase domain and is classified as 
deleterious by most bioinformatic prediction algorithms (SIFT, 
PolyPhen, LRT, MutationTaster, Mutation Assessor, PROVEAN, 
CADD, GERP and SiPhy). One model to account for the differ-
ence in p.Arg261His and LOF variant toxicity could be a correlation 
between phenotypic expression and the predicted extent of NEK1 LOF. 
This model would also be consistent with previous findings that 
homozygosity for NEK1 LOF variants causes a severe developmental 
phenotype; short rib polydactyly syndrome type II (SRPS)13. In the 
current study, no individuals carried multiple LOF alleles. However, in 
SRPS, homozygous carriers of NEK1 LOF variants have been reported 
to exhibit a 64% reduction of NEK1 mRNA levels whereas unaffected 
heterozygous parents exhibit a 30–40% reduction13.
NEK1 represents one of 11 members of the highly conserved 
NIMA kinase family, which has conserved functions in cell-cycle 
progression and mitosis. In postmitotic cells, NEK1 is a primary 
regulator of the formation of nonmotile primary cilium14,15. 
Disruption in the structure or function of primary cilia has been 
linked to neurological defects such as brain dysgenesis, hydro-
cephalus and intellectual disability16,17, and abnormalities in cilia 
number, structure and microtubule state occur in fibroblasts derived 
from SRPS patients homozygous for NEK1 truncation variants13. 
In vitro disruption of the activity of other neuronally expressed 
NEK family members has similarly been shown to disrupt neuronal 
morphology, neurite outgrowth, microtubule stability and microtubule 
dynamics18,19. Microtubule integrity and kinesin and dynein 
intraflagellar transport are essential to maintain cilia structure and 
function. This is of particular relevance as disruption of the microtu-
bule cytoskeleton has been associated to the development of ALS3, and 
mutations of the dynein subunit dynactin are associated with motor 
neuron degeneration20. Additionally, motor neurons derived from 
mice expressing human SOD1 G93A show a selective loss of cilia both 
in vitro and in vivo21. Besides its role in ciliogenesis, NEK1 is also known 
to regulate mitochondrial membrane permeability22 and DNA repair23. 
Both of these processes have been extensively investigated in relation 
to ALS, and have been postulated to explain the toxicity of ALS- 
associated mutations in SOD1 and FUS24,25. Mutations in DNA-repair 
genes cause several early-onset neurological phenotypes, and multiple 
lines of evidence suggest defective DNA repair may contribute to both 
late-onset neurodegeneration and brain aging in general26. For exam-
ple, oxidative damage and DNA strand breaks have been observed 
to be elevated in ALS, Alzheimer’s disease and Parkinson’s disease 
cases27, and a recent large-scale genome-wide association study 
(GWAS) implicated DNA-repair genes as age-of-onset modifiers in 
Huntington’s disease28. The pathological importance of DNA dam-
age in ALS, and whether modifier effects observed in Huntington’s 
disease may generalize to repeat-expansion disorders such as C9orf72- 
associated ALS, constitute important questions to be addressed. 
Finally, through its coiled-coil domain, NEK1 has been shown to 
interact with multiple other proteins of potential importance, includ-
ing the ALS-associated proteins VAPB and ALS2 (ref. 7) and the 
axonal outgrowth regulator FEZ1 (ref. 29).
Data access. Full details of variants identified in ALS patients 
are publicly available through the ALS Variant Server at http://als.
umassmed.edu/.
URLs. Exome Variant Server, NHLBI Exome Sequencing Project 
(ESP), http://evs.gs.washington.edu/EVS/; Exome Aggregation 
Consortium (ExAC), http://exac.broadinstitute.org; ALS Variant 
Server http://als.umassmed.edu/.
MeTHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
Acknowledgments
We acknowledge all of the study participants and our collaborators for enabling 
this study by graciously providing samples for this study. Funding was provided by  
US National Institutes of Health (NIH)/National Institute of Neurological Disorders 
and Stroke (NINDS) (R01NS073873, J.E.L.), the American ALS Association  
(N.T., V.S., C.E.S., J.E.L. and R.H.B.Jr.), the Motor Neuron Disease (MND) 
Association (N.T., V.S., C.E.S. and J.E.L.), the Angel Fund (R.H.B.Jr.), Project ALS/
P2ALS (R.H.B.Jr.), the ALS Therapy Alliance (R.H.B.Jr. and J.E.L.), The 
Netherlands ALS Foundation (Project MinE; J.H.V. and L.H.v.d.B.), ALS liga 
Belgium (P.V.D. and W.Ro.), Suna and Inan Kirac Foundation (N.A.B.). Computer 
resources for this study were provided by the Green High Performance Computing 
Center at the University of Massachusetts Medical School. L.H.v.d.B. received 
grants from the Netherlands Organization for Health Research and Development 
(Vici Scheme; the SOPHIA and STRENGTH projects through the EU Joint 
Programme – Neurodegenerative Disease Research, JPND). I.P.B. received grant 
funding from the National Health and Medical Research Council (NHMRC) of 
Australia (1095215, 1107644). P.C.S. was supported through the auspices of H. 
Robert Horvitz (Massachusetts Institute of Technology), an Investigator of the 
Howard Hughes Medical Institute. M.A.v.E. received a grant from the Netherlands 
Organization for Health Research and Development (Veni scheme) and travel 
table 1 FAls discovery analysis identifies candidate genes
Gene ALS
ALS  
frequency Control
Control  
frequency OR OR 95% CI P
NEK1 12 0.0117 14 0.0019 8.2 3.7–18.0 1.7 × 10−6
ATRN 8 0.0078 7 0.0010 10.3 3.6–29.6 3.7 × 10−5
STX12 4 0.0039 1 0.0001 33.1 5.8–339.0 9.7 × 10−5
CREB3L2 4 0.0039 0 0.0000 64.9 6.6–8695.3 1.1 × 10−4
DCC 4 0.0039 2 0.0003 18.6 4.1–108.1 3.1 × 10−4
WDR49 5 0.0049 2 0.0003 15.8 3.5–92.1 4.4 × 10−4
KIF5A 7 0.0068 8 0.0011 7.1 2.5–19.7 4.8 × 10−4
C1QTNF7 12 0.0117 26 0.0036 3.6 1.8–7.1 6.7 × 10−4
PEAK1 5 0.0049 3 0.0004 11.6 2.9–51.5 7.5 × 10−4
BIRC6 10 0.0098 18 0.0025 4.3 1.9–9.3 8.4 × 10−4
ZSCAN5B 4 0.0039 2 0.0003 16.3 3.3–98.0 8.8 × 10−4
RVB analysis results for all genes exhibiting case association at P < 1 × 10−3 in FALS 
discovery cohort.
©
20
16
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
  ADVANCE ONLINE PUBLICATION Nature GeNetics
l e t t e r s
grants from Baxter. This is an EU Joint Programme - Neurodegenerative Disease 
Research (JPND) project. The project is supported through the following funding 
organizations under the aegis of JPND (United Kingdom, Medical Research 
Council; Netherlands, ZonMW; Italy, Ministero dell’Istruzione, dell’Università e 
della Ricerca; Belgium, Fonds Wetenschappelijk Onderzoek; Germany, 
Bundesministerium für Bildung und Forschung). C.E.S. and A.A.-C. receive salary 
support from the National Institute for Health Research (NIHR) Dementia 
Biomedical Research Unit at South London and Maudsley NHS Foundation Trust 
and King’s College London. The work leading up to this publication was funded by 
the European Community’s Health Seventh Framework Programme (FP7/2007–
2013; grant agreement number 259867). Samples used in this research were in part 
obtained from the UK National DNA Bank for MND Research, funded by the 
MND Association and the Wellcome Trust. I.R.C.C.S. Istituto Auxologico Italiano; 
AriSLA - Fondazione Italiana di Ricerca per la SLA co-financed with support of 
“5x1000” - Healthcare Research of the Italian Ministry of Health (grants 
EXOMEFALS 2009 and NOVALS 2012 (N.T., C.T., C.G., V.S. and J.E.L.)),  
(grant RepeatALS 2013 (S.D.T. and L.C.)), Italian Ministry of Health (grant GR-
2011-02347820 - IRisALS (N.T., C.T. and D.C.)). This work was supported by a 
grant from the Flemish agency for Innovation by Science and Technology (IWT, 
Project MinE), the Interuniversity Attraction Poles (IUAP) program P7/16 of the 
Belgian Federal Science Policy Office, by the FWO-Vlaanderen under the frame of  
E-RARE-2, the ERA-Net for Research on Rare Diseases (PYRAMID), by a EU 
JPND project (STRENGTH). P.V.D. is supported by FWO Vlaanderen and the 
Belgian ALS liga. In Australia, this work was supported by a Leadership Grant to  
I.P.B. from MND Australia and an NHMRC fellowship (1092023) to K.L.W. G.A.R. 
is funded by the Canadian Institute of Health Research (CIHR), Genome-wide 
exon capture for targeted resequencing in patients with FALS (#208973) the 
Muscular Dystrophy Association, and Whole exome sequencing in patients with 
FALS (#153959). We thank JMB Vianney de Jong for collection of clinical data.  
C.S.L. is recipient of Tim E. Noël fellowship from ALS society of Canada. W.Ro. is 
supported through the E. von Behring Chair for Neuromuscular and 
Neurodegenerative Disorders, the Laevers Fund for ALS Research, the ALS Liga 
België, the fund ‘Een Hart voor ALS’ and the fund ‘Opening the Future’. The 
research leading to these results has received funding from the European Research 
Council und the European’s Seventh Framework Programme (FP7/2007-
2013)/ERC grant agreement 340429 and from the Geneeskundige Stichting 
Koningin Elisabeth (G.S.K.E.). M.S. and C.D. were supported by the Deutsche 
Forschungsgemeinschaft, SE697/4-1, BMBF EnergI and the Deutsche Gesellschaft 
für Muskelkranke, Project He 2/2. This work was supported in whole or in parts by 
a grant from the German Federal Ministry of Education and Research (JPND 
STRENGTH consortium; German network for ALS research MND-NET), the 
Charcot Foundation for ALS Research, the virtual Helmholtz Institute “RNA-
Dysmetabolismus in ALS and FTD” and the DFG-funded Swabian ALS Registry. 
A.Ch. is funded in part by Italian Ministry of Health (Ricerca Sanitaria Finalizzata 
2010, grant RF-2010-2309849, project EXPALS), the European Community’s 
Health Seventh Framework Programme (FP7/2007-2013 under grant agreements 
259867), the Joint Programme - Neurodegenerative Disease Research (Italian 
Ministry of Education and University) (Sophia, and Strength Projects),  
A.C. is funded in part by Italian Ministry of Health (Ricerca Sanitaria Finalizzata 
2010, grant GR-2010-2320550, project EXTRALS) and Fondazione Vialli e Mauro 
per la Ricerca sulla SLA onlus (grant #4). FUNDELA – Spanish Foundation to the 
development of ALS research, ISCIII – Carlos III Institute / Fondo de Investigación 
Sanitaria of Spain (PI10/00092; PI14/00088), ADELA – ALS Spanish Association. 
Part of this work was carried out on the Dutch national e-infrastructure with the 
support of SURF Foundation. The Alzheimer’s Disease Sequencing Project 
(ADSP), phs000572.v7.p4, is comprised of two Alzheimer’s disease (AD) genetics 
consortia and three National Human Genome Research Institute (NHGRI) funded 
Large Scale Sequencing Centers (LSSC). The two AD genetics consortia are the 
Alzheimer’s Disease Genetics Consortium (ADGC) funded by the National 
Institute on Aging (NIA) (U01 AG032984), and the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), 
the National Heart, Lung, and Blood Institute (NHLBI), other NIH institutes and 
other foreign governmental and nongovernmental organizations. The Discovery 
Phase analysis of sequence data is supported through UF1AG047133 to  
G.D. Schellenberg, L.A. Farrer, M.A. Pericak-Vance, R. Mayeux and J.L. Haines; 
U01AG049505 to S. Seshadri; U01AG049506 to E. Boerwinkle; U01AG049507 to 
E. Wijsman; and U01AG049508 to A.M.Goate. The ADGC cohorts include: Adult 
Changes in Thought (ACT), the Alzheimer’s Disease Centers (ADC), the Chicago 
Health and Aging Project (CHAP), the Memory and Aging Project (MAP), Mayo 
Clinic, Mayo Parkinson’s Disease controls, University of Miami, the Multi-
Institutional Research in Alzheimer’s Genetic Epidemiology Study (MIRAGE), the 
National Cell Repository for Alzheimer’s disease (NCRAD), the National Institute 
on Aging Late Onset Alzheimer’s Disease Family Study (NIA-LOAD), the Religious 
Orders Study (ROS), the Texas Alzheimer’s Research and Care Consortium 
(TARC), Vanderbilt University/Case Western Reserve University (VAN/CWRU), 
the Washington Heights-Inwood Columbia Aging Project (WHICAP) and the 
Washington University Sequencing Project (WUSP), the Columbia University 
Hispanic-Estudio Familiar de Influencia Genetica de Alzheimer (EFIGA), the 
University of Toronto, and Genetic Differences (GD). The CHARGE cohorts, with 
funding provided by 5RC2HL102419 and HL105756, include the following: 
Atherosclerosis Risk in Communities (ARIC) Study which is carried out as a 
collaborative study supported by NHLBI contracts (HHSN268201100005C, 
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, 
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and 
HHSN268201100012C), Austrian Stroke Prevention Study (ASPS), Cardiovascular 
Health Study (CHS), Erasmus Rucphen Family Study (ERF), Framingham Heart 
Study (FHS), and Rotterdam Study (RS). The three LSSC are: the Human Genome 
Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad 
Institute Genome Center (U54HG003067), and the Washington University 
Genome Institute (U54HG003079). Biological samples and associated phenotypic 
data used in primary data analyses were stored at Study Investigators institutions, 
and at the National Cell Repository for Alzheimer’s Disease (NCRAD, 
U24AG021886) at Indiana University funded by NIA. Associated phenotypic data 
used in primary and secondary data analyses were provided by Study Investigators, 
the NIA-funded Alzheimer’s Disease Centers (ADCs), and the National 
Alzheimer’s Coordinating Center (NACC, U01AG016976) and the National 
Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS, 
U24AG041689) at the University of Pennsylvania, funded by NIA, and at the 
Database for Genotypes and Phenotypes (dbGaP) funded by NIH. Contributors to 
the Genetic Analysis Data included Study Investigators on projects that were 
individually funded by NIA, and other NIH institutes, and by private US 
organizations, or foreign governmental or nongovernmental organizations. We 
thank people with MND, their families and control individuals for their 
participation in this project.
AUtHoR contRIBUtIons
Sample collection, preparation and clinical evaluation: P.T.C.v.D., A.M.D., N.T., 
F.P.D., W.v.R., K.R.v.E., A.R.J., P.K., A.S., W.S., B.N.S., M.A.v.E., S.D.T., A. Kenna, 
J.W.M., C. Tiloca, R.L.M., C.V., C. Troakes, C. Colombrita, G.M., A. Calvo, F.V., 
S.A.-S., A. King, D.C., J.d.B., F.B., A.J.v.d.K., M.d.V., A.L.M.A.t.A., P.C.S., D.M.-Y.,  
M.P., S.A., J.L.M.-B., T.M.S., T.M., K.E.M., S.D’A., L.M., G.P.C., R.D.B., M.C., S.G., 
G.Q., C.B., V.P., B.C., S.C., C. Cereda, L.C., G.S., G.L., K.L.W., P.N.L., G.A.N., I.P.B., 
C.S.L., P.A.D., G.A.R., H.P., P.J.S., M.R.T., K.T., F.T., K.B.B., M.V.B., R.R., J.E.-P., 
A.G.-R., P.V.D., W.R., A. Chio, C.G., C.D., M.S., A.R., J.D.G., J.S.M., N.A.B., O.H., 
A.C.L., P.M.A., J.H.W., R.H.B., A.A.-C., V.S., C.E.S., L.H.v.d.B., J.H.V. and J.E.L. 
Experiments and data analysis: K.P.K., P.T.C.v.D., A.M.D., N.T., B.J.K., F.P.D., 
W.v.R., K.R.v.E., A.R.J., P.K., A.S., W.S., B.N.S., M.A.v.E., S.D.T., A. Kenna, J.W.M., 
C.F., C.T., R.L.M., C.V., C. Troakes, C. Colombrita, G.M., A. Calvo, F.V., S.A.-S., 
A. King, D.C., P.C.S., D.M.-Y., K.L.W., C.S.L., P.A.D., M.v.B., R.R., J.E.-P., A.G.-R., 
P.v.D., W.R., A. Chio, C.G., C.D., M.S., A.R., J.D.G., J.S.M., N.A.B., O.H., A.C.L., 
P.M.A., J.H.W., R.H.B.Jr, A.A.-C., V.S., C.E.S., L.H.v.d.B., J.H.V. and J.E.L. Scientific 
planning and direction: K.P.K., P.T.C.v.D., A.M.D., N.T., B.J.K., C.F., I.P.B., C.S.L., 
P.A.D., G.A.R., H.P., P.J.S., M.R.T., K.T., F.T., K.B.B., M.v.B., R.R., J.E.-P., A.G.-R., 
P.v.D., W.R., A. Chio, C.G., C.D., M.S., A.R., J.D.G., J.S.M., N.A.B., O.H., A.C.L., 
P.M.A., J.H.W., R.H.B.Jr, A.A.-C., V.S., C.E.S., L.H.v.d.B., J.H.V. and J.E.L. Initial 
manuscript preparation: K.P.K., P.T.C.v.D., A.M.D., N.T., A.A.-C., V.S., C.E.S., 
L.H.v.d.B., J.H.V. and J.E.L. 
comPetIng FInAncIAl InteRests
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Gilissen, C., Hoischen, A., Brunner, H.G. & Veltman, J.A. Unlocking Mendelian 
disease using exome sequencing. Genome Biol. 12, 228 (2011).
2. Ng, S.B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki 
syndrome. Nat. Genet. 42, 790–793 (2010).
3. Smith, B.N. et al. Exome-wide rare variant analysis identifies TUBA4A mutations 
associated with familial ALS. Neuron 84, 324–331 (2014).
4. Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single 
nucleotide variants in the human genome. Nucleic Acids Res. 42, 13534–13544 
(2014).
5. Shihab, H.A. et al. Predicting the functional, molecular, and phenotypic 
consequences of amino acid substitutions using hidden Markov models. Hum. 
Mutat. 34, 57–65 (2013).
6. Reid, E. et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic 
paraplegia (SPG10). Am. J. Hum. Genet. 71, 1189–1194 (2002).
7. Cirulli, E.T. et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk 
genes and pathways. Science 347, 1436–1441 (2015).
©
20
16
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNetics  ADVANCE ONLINE PUBLICATION 5
l e t t e r s
8. Brenner, D. et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 
139, e28 (2016).
9. Renton, A.E., Chiò, A. & Traynor, B.J. State of play in amyotrophic lateral sclerosis 
genetics. Nat. Neurosci. 17, 17–23 (2014).
10. Kenna, K.P. et al. Delineating the genetic heterogeneity of ALS using targeted 
high-throughput sequencing. J. Med. Genet. 50, 776–783 (2013).
11. Lattante, S. et al. Contribution of major amyotrophic lateral sclerosis genes to the 
etiology of sporadic disease. Neurology 79, 66–72 (2012).
12. Chiò, A. et al. Extensive genetics of ALS: a population-based study in Italy. 
Neurology 79, 1983–1989 (2012).
13. Thiel, C. et al. NEK1 mutations cause short-rib polydactyly syndrome type majewski. 
Am. J. Hum. Genet. 88, 106–114 (2011).
14. Shalom, O., Shalva, N., Altschuler, Y. & Motro, B. The mammalian Nek1 kinase is 
involved in primary cilium formation. FEBS Lett. 582, 1465–1470 (2008).
15. White, M.C. & Quarmby, L.M. The NIMA-family kinase, Nek1 affects the stability 
of centrosomes and ciliogenesis. BMC Cell Biol. 9, 29 (2008).
16. Lee, J.H. & Gleeson, J.G. The role of primary cilia in neuronal function. Neurobiol. 
Dis. 38, 167–172 (2010).
17. Lee, L. Riding the wave of ependymal cilia: genetic susceptibility to hydrocephalus 
in primary ciliary dyskinesia. J. Neurosci. Res. 91, 1117–1132 (2013).
18. Cohen, S., Aizer, A., Shav-Tal, Y., Yanai, A. & Motro, B. Nek7 kinase accelerates 
microtubule dynamic instability. Biochim. Biophys. Acta 1833, 1104–1113 
(2013).
19. Chang, J., Baloh, R.H. & Milbrandt, J. The NIMA-family kinase Nek3 regulates 
microtubule acetylation in neurons. J. Cell Sci. 122, 2274–2282 (2009).
20. Puls, I. et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455–456 
(2003).
21. Ma, X., Peterson, R. & Turnbull, J. Adenylyl cyclase type 3, a marker of primary 
cilia, is reduced in primary cell culture and in lumbar spinal cord in situ in G93A 
SOD1 mice. BMC Neurosci. 12, 71 (2011).
22. Chen, Y., Craigen, W.J. & Riley, D.J. Nek1 regulates cell death and mitochondrial 
membrane permeability through phosphorylation of VDAC1. Cell Cycle 8, 257–267 
(2009).
23. Pelegrini, A.L. et al. Nek1 silencing slows down DNA repair and blocks DNA 
damage-induced cell cycle arrest. Mutagenesis 25, 447–454 (2010).
24. Sama, R.R., Ward, C.L. & Bosco, D.A. Functions of FUS/TLS from DNA repair to stress 
response: implications for ALS. ASN Neuro 6, 1759091414544472 (2014).
25. Tafuri, F., Ronchi, D., Magri, F., Comi, G.P. & Corti, S. SOD1 misplacing and 
mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front. Cell. 
Neurosci. 9, 336 (2015).
26. Madabhushi, R., Pan, L. & Tsai, L.H. DNA damage and its links to neurodegeneration. 
Neuron 83, 266–282 (2014).
27. Coppedè, F. & Migliore, L. DNA damage in neurodegenerative diseases. Mutat. Res. 
776, 84–97 (2015).
28. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Identification of 
genetic factors that modify clinical onset of Huntington’s disease. Cell 162, 
516–526 (2015).
29. Surpili, M.J., Delben, T.M. & Kobarg, J. Identification of proteins that interact with 
the central coiled-coil region of the human protein kinase NEK1. Biochemistry 42, 
15369–15376 (2003).
kevin P kenna1,40, Perry t c van doormaal2,40, Annelot m dekker2,40, nicola ticozzi3,4,40, Brendan J kenna1, 
Frank P diekstra2, wouter van Rheenen2, kristel R van eijk2, Ashley R Jones5, Pamela keagle1,  
Aleksey shatunov5, william sproviero5, Bradley n smith5, michael A van es2, simon d topp5, Aoife kenna1, 
Jack w miller5, claudia Fallini1, cinzia tiloca3,6, Russell l mclaughlin7, caroline Vance5, claire troakes5, 
claudia colombrita3,4, gabriele mora8, Andrea calvo9, Federico Verde3,4, safa Al-sarraj5, Andrew king5, 
daniela calini3, Jacqueline de Belleroche10, Frank Baas11, Anneke J van der kooi12, marianne de Visser12, 
Anneloor l m A ten Asbroek11, Peter c sapp1, diane mckenna-Yasek1, meraida Polak13, seneshaw Asress13, 
José luis muñoz-Blanco14, tim m strom15, thomas meitinger16, karen e morrison17, slAgen consortium18, 
giuseppe lauria19, kelly l williams20, P nigel leigh21, garth A nicholson20,22, Ian P Blair20, claire s leblond23, 
Patrick A dion23, guy A Rouleau23, Hardev Pall24,25, Pamela J shaw26, martin R turner26, kevin talbot26,  
Franco taroni27, kevin B Boylan28, marka Van Blitterswijk29, Rosa Rademakers29, Jesús esteban-Pérez30,31, 
Alberto garcía-Redondo30,31, Phillip Van damme32,33, wim Robberecht32,33, Adriano chio9, cinzia gellera27, 
carsten drepper34,35, michael sendtner34, Antonia Ratti3,4, Jonathan d glass13, Jesús s mora36, nazli A Basak37, 
orla Hardiman7, Albert c ludolph38, Peter m Andersen39, Jochen H weishaupt38, Robert H Brown, Jr1,  
Ammar Al-chalabi5, Vincenzo silani3,4,41, christopher e shaw5,41, leonard H van den Berg2,41,  
Jan H Veldink2,41& John e landers1,41
1Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 2Department of Neurology Brain Centre, Brain Centre Rudolf 
Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands. 3Department of Neurology, IRCCS Istituto Auxologico Italiano, Milan, Italy. 4Department of 
Pathophysiology and Transplantation, ‘Dino Ferrari’ Center, Università degli Studi di Milano, Milan, Italy. 5Maurice Wohl Clinical Neuroscience Institute, King’s College 
London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, London, UK. 6Doctoral School in Molecular Medicine, 
Department of Sciences and Biomedical Technologies, Università degli Studi di Milano, Milan, Italy. 7Academic Unit of Neurology, Trinity Biomedical Sciences 
Institute, Trinity College Dublin, Dublin, Ireland. 8Salvatore Maugeri Foundation, IRCSS, Scientific Institute of Milano, Milan, Italy. 9‘Rita Levi Montalcini’ Department 
of Neuroscience, ALS Centre, University of Torino, Turin, Italy. 10Neurogenetics Group, Division of Brain Sciences, Imperial College London, London, UK.  
11Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. 12Department of Neurogenetics and Neurology, 
Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. 13Department of Neurology, Emory University, Atlanta, Georgia, USA.  
14Unidad de ELA, Instituto de Investigación Hospital Gregorio Marañón de Madrid, Madrid, Spain. 15Institute of Human Genetics, Helmholtz Zentrum München–
German Research Center for Environmental Health, Neuherberg, Germany. 16Institute of Human Genetics, Technische Universität München, Munich, Germany. 
17Faculty of Medicine, University of Southampton, Southampton, UK. 18A list of members and affiliations appears at the end of the paper. 193rd Neurology Unit, 
Motor Neuron Diseases Center, Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, Milan, Italy. 20Faculty of Medicine and Health Sciences, Macquarie University,  
Sydney, New South Wales, Australia. 21Trafford Centre for Medical Research, Brighton and Sussex Medical School, Falmer, UK. 22ANZAC Research Institute, Concord 
Hospital, University of Sydney, Sydney, New South Wales, Australia. 23Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, 
Montreal, Quebec, Canada. 24Institute of Clinical Studies, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.  
25Department of Neurology, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK. 26Nuffield Department of Clinical Neurosciences, University of 
Oxford, Oxford, UK. 27Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, Milan, Italy. 28Department 
of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA. 29Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. 30Unidad de ELA, Instituto de 
Investigación Hospital 12 de Octubre de Madrid, Madrid, Spain. 31Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) U-723, Madrid, 
Spain. 32Laboratory of Neurobiology, Department of Neurosciences, KU Leuven and Vesalius Research Centre, VIB, Leuven, Belgium. 33Department of Neurology,  
University Hospitals, Leuven, Belgium. 34Institute of Clinical Neurobiology, University Hospital Würzburg, Würzburg, Germany. 35Department of Child and  
Adolescent Psychiatry, University Hospital of Würzburg, Würzburg, Germany. 36ALS Unit/Neurology, Hospital San Rafael, Madrid, Spain. 37NDAL, Department of 
Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey. 38Neurology Department, Ulm University, Ulm, Germany. 39Department of Pharmacology  
and Clinical Neuroscience, Umeå University, Umeå, Sweden. 40These authors contributed equally to this work. 41These authors jointly directed this work. 
Correspondence should be addressed to J.H.V. (j.h.veldink@umcutrecht.nl). 
©
20
16
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
6  ADVANCE ONLINE PUBLICATION Nature GeNetics
l e t t e r s
42Department of Health Sciences, University of Eastern Piedmont, Novara, Italy. 43ALS Center, Department of Neurology, ‘A. Avogadro’ University of Eastern 
Piedmont, Novara, Italy. 44Neurology Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. 45Experimental Neurobiology Laboratory,  
‘C. Mondino’ National Institute of Neurology Foundation, IRCCS, Pavia, Italy. 46Department of Neurological Sciences, University of Pavia, Pavia, Italy.  
47Department of Neurosciences, University of Padova, Padova, Italy.
slAgen consortium: 
sandra d’Alfonso42, letizia mazzini43, giacomo P comi4,44, Roberto del Bo4,44, mauro ceroni45,46,  
stella gagliardi45, giorgia Querin47, cinzia Bertolin47, Viviana Pensato27, Barbara castellotti27, stefania corti4,44,  
cristina cereda45, lucia corrado42 & gianni sorarù47
©
20
16
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNeticsdoi:10.1038/ng.3626
ONLINe MeTHODS
FALS discovery cohort. The FALS discovery cohort included 1,376 FALS 
patients and 13,883 non-ALS controls analyzed by exome sequencing. Patients 
were recruited at specialist clinics in Ireland (n = 18), Italy (n = 143), Spain 
(n = 49), the UK (n = 219), the United States (n = 511), the Netherlands (n = 50), 
Canada (n = 34), Belgium (n = 12), Germany (n = 202), Turkey (n = 47) and 
Australia (n = 91). Variants occurring at very low frequency in the general 
population (ExAC MAF <0.0001), which have been both previously reported 
as ALS-associated and annotated as either ‘pathogenic’ or ‘likely pathogenic’ 
by ClinVar within the ten genes, were considered to be pathogenic mutations. 
The breakdown of the 72 mutations observed in the final cohort included 
the following: SOD1 (28), TARDBP (12), FUS (9), PFN1 (6), TBK1 (1), TUBA4A 
(4), UBQLN2 (4), VAPB (2) and VCP (6). An additional 26 cases harbored 
a repeat expansion in the C9orf72 gene. Controls included 29 internal 
samples and samples obtained from dbGAP30. Sequencing obtained from 
dbGAP was generated under the following projects: Genetic Epidemiology 
of chronic obstructive pulmonary disease (COPD) (COPDGene) phs000179; 
NHLBI Grand Opportunity Exome Sequencing Project (GO-ESP): Lung 
Cohorts Exome Sequencing Project (cystic fibrosis) phs000254; NHLBI 
GO-ESP: Women’s Health Initiative Exome Sequencing Project (WHI)-
WHISP phs000281; NHLBI GO-ESP: Lung Cohorts Exome Sequencing 
Project (pulmonary arterial hypertension) phs000290; NHLBI GO-ESP: 
Lung Cohorts Exome Sequencing Project (Lung Health Study of Chronic 
Obstructive Pulmonary Disease) phs000291; NHLBI GO-ESP: Lung 
Cohorts Exome Sequencing Project (COPDGene) phs000296; NHLBI 
Framingham Heart Study Allelic Spectrum Project phs000307; NHLBI 
GO-ESP: Family Studies (Thoracic aortic aneurysms leading to acute aor-
tic dissections) phs000347; NHLBI GO-ESP Family Studies: pulmonary 
arterial hypertension phs000354; NHLBI GO-ESP: Family Studies: (familial 
atrial fibrillation) phs000362; NHLBI GO-ESP: Heart Cohorts Exome 
Sequencing Project (ARIC) phs000398; NHLBI GO-ESP: Heart Cohorts Exome 
Sequencing Project (CHS) phs000400; NHLBI GO-ESP: Heart Cohorts Exome 
Sequencing Project (FHS) phs000401; NHLBI GO-ESP: Heart Cohorts Exome 
Sequencing Project (JHS) phs000402; NHLBI GO-ESP: Heart Cohorts Exome 
Sequencing Project (MESA) phs000403; NHLBI GO-ESP: Lung Cohorts Exome 
Sequencing Project (asthma) phs000422; Jackson Heart Study Allelic Spectrum 
Project phs000498; NHLBI GO-ESP Family Studies: Idiopathic Bronchiectasis 
phs000518; Alzheimer’s Disease Sequencing Project (ADSP) phs000572; 
NHLBI GO-ESP: Family Studies (Hematological Cancers) phs000632; Building 
on GWAS for NHLBI diseases: the US CHARGE consortium (CHARGE-S): 
FHS phs000651; Building on GWAS for NHLBI diseases: The US CHARGE 
Consortium (CHARGE-S): CHS phs000667; Building on GWAS for NHLBI 
Diseases: the US CHARGE Consortium (CHARGE-S): ARIC phs000668; NIH 
Exome Sequencing of FALS Project phs000101.v4.p1. Familial history was con-
sidered positive for ALS if the proband had at least one affected relative within 
three generations. We received approval for this study from the institutional 
review boards of the participating centers, and written informed consent was 
obtained from all patients (consent for research).
SALS replication cohort. The SALS replication cohort included 2,387 SALS 
cases and 1,093 controls analyzed by whole-genome sequencing, and 5,834 
SALS cases and 4,117 controls analyzed by exome chip. All individuals were 
recruited at specialist clinics in Ireland, Italy, Spain, the UK, the United States, 
the Netherlands and Belgium. Details of sample contributions per country 
are shown in Figure 2. Evaluation of C9orf72 status was performed in 2,387 
SALS cases and 166 (7%) displayed a repeat expansion. We received approval 
for this study from the institutional review boards of the participating cent-
ers, and written informed consent was obtained from all patients (consent 
for research).
Exome sequencing. Exome sequencing of patients was performed as 
previously described3. Raw sequence data for controls was obtained from 
dbGaP. Sequence reads were aligned to human reference GRCh37 using 
Burrows–Wheeler aligner (BWA) and processed according to recommended 
best practices31. Variant detection and genotyping were performed using the 
GATK HaplotypeCaller. Variant quality control was performed using the 
GATK variant quality score recalibration method, with a VQSLOD cutoff of 
2.27 (truth set sensitivity of 99%). A minimum variant quality by depth (QD) 
score of 2 was also imposed and all genotypes associated with genotype qual-
ity (GQ) < 20 were reset to missing. Variants were also excluded in the event 
of case or control call rates < 70% (post genotype QC). Exome sequencing 
data was not used to infer the presence or absence of indels due to the limited 
sensitivity and comparatively high false positive rates associated with available 
calling algorithms32.
Genome sequencing. Whole-genome sequencing of 2,387 SALS samples 
and 1,093 controls was performed with Illumina’s FastTrack services using 
PCR free library preparation and paired-end (100 bp or 150 bp) sequencing 
on the HiSeq 2500 or Hiseq X platform (Illumina) to yield 35× coverage at 
minimum. BWA was used to align sequencing reads to genome build hg19, 
and the Isaac variant caller was used to call single-nucleotide variants (SNVs), 
insertions and deletions (indels)33. Both the aligned and unaligned reads were 
delivered in binary sequence alignment/map format (BAM) together with 
variant call format (VCF) files containing the SNVs and indels. gVCF files 
were generated per individual, and variants that failed the Isaac-based quality 
filter were excluded.
Exome chip. A total of 5,815 ALS patients and 4,614 healthy controls from 
the Netherlands, Belgium, Germany, Ireland, Italy, Spain and the UK were 
included. Genotyping was conducted using Illumina HumanExome-12v1 
BeadChips in accordance with the manufacturer’s recommendations. 
The GenTrain 2.0 clustering algorithm was used for genotype calling, as 
implemented in the Illumina GenomeStudio software package. Initial genotype 
calls were made based on the HumanExome clusterfile provided by Illumina. 
More accurate cluster boundaries were determined based on the actual study 
data, after the exclusion of samples with a GenCall quality score in the lower 
10th percentile of the distribution across all variants genotyped (p10GC) < 
0.38 or call rate < 0.99. Subsequently, the excluded samples were added back 
into the data set, and new genotypes calls were made using the previously 
obtained cluster boundaries.
Sample filtering. Samples from the FALS discovery and SALS replication 
cohorts were excluded from analysis in the event of failing to meet 
genotype call rate, heterozygosity, gender concordance, duplication, related-
ness or population stratification filters as summarized in Supplementary 
Figures 1 and 7. All samples from the FALS cohort were required to exhibit 
filtered exome-wide call rates > 70%. For both the FALS and SALS cohorts, 
PLINK (v1.07)34 was used to define an LD-pruned (r2 < 0.5, window 
size = 50, step = 5) set of autosomal markers with MAF > 0.01 and P > 0.001 
for deviation from Hardy–Weinberg equilibrium. These marker sets were then 
used to calculate inbreeding coefficients for use in heterozygosity filtering, 
identify study duplicates, conduct relatedness filtering, perform tests of pair-
wise population concordance for stratification filtering, conduct PCA for a 
second round of stratification filtering and conduct PCA to generate covari-
ates for stratification correction in RVB analysis and single-variant analysis 
of filtered cohorts. Samples from the SALS replication cohort were required 
to exhibit no relatedness/duplication with samples from the FALS discovery 
cohort. PLINK was used to calculate inbreeding coefficients, test for discord-
ance in reported and SNV predicted gender and conduct tests of pairwise 
population concordance. Identification of sample duplicates and sample relat-
edness was performed using KING35. PCA was conducted using genome-wide 
complex trait analysis (GCTA)36. Details of results from population stratifica-
tion analysis are provided in Supplementary Figures 2 and 8.
Statistical analyses. RVB analyses were performed by logistic regression 
of case–control status to number of minor alleles observed per sample per 
gene3,37. Results from underpowered tests (≤3 observations in combined 
case–control cohort) were excluded and did not contribute to assessments 
of genomic inflation. Variants were included for RVB analyses on the basis 
of MAF within the combined case–control cohort, MAF within the 1000 
Genomes project38, and pathogenicity predictions generated using snpEFF 
(single nucleotide polymorphism effect)39, PolyPhen2 (polymorphism 
phenotyping version 2)40, SIFT (sorting intolerant from tolerant)41, LRT 
(likelihood ratio test)42, MutationTaster43, MutationAssessor44, FATHMM 
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